FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?

Authorized Users Only
2018
Authors
Đurasinović, Vladislava T.
Mihaljević, Biljana
Šipetić-Grujičić, Sandra B.
Ignjatović, Svetlana
Trajković, Goran
Todorović-Balint, Milena R.
Antić, Darko
Bila, Jelena S.
Anđelić, Bosko M.
Jelicić, Jelena J.
Vuković, Vojin M.
Nikolić, Aleksandra M.
Klek, Stanislaw
Article (Published version)
Metadata
Show full item record
Abstract
Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the ...Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D lt 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D lt 19.6 nmol/l had a significantly shorter PFS.

Keywords:
25(OH)D level / Lymphoma
Source:
Synthetic Communications, 2018, 26, 8, 2825-2832
Publisher:
  • Springer, New York
Projects:
  • Biomarkers of organ damage and dysfunction (RS-175036)

DOI: 10.1007/s00520-018-4101-9

ISSN: 0941-4355

PubMed: 29511954

WoS: 000436242800037

Scopus: 2-s2.0-85049436913
[ Google Scholar ]
3
4
URI
http://farfar.pharmacy.bg.ac.rs/handle/123456789/3236
Collections
  • Radovi istraživača / Researchers’ publications
Institution
Pharmacy
TY  - JOUR
AU  - Đurasinović, Vladislava T.
AU  - Mihaljević, Biljana
AU  - Šipetić-Grujičić, Sandra B.
AU  - Ignjatović, Svetlana
AU  - Trajković, Goran
AU  - Todorović-Balint, Milena R.
AU  - Antić, Darko
AU  - Bila, Jelena S.
AU  - Anđelić, Bosko M.
AU  - Jelicić, Jelena J.
AU  - Vuković, Vojin M.
AU  - Nikolić, Aleksandra M.
AU  - Klek, Stanislaw
PY  - 2018
UR  - http://farfar.pharmacy.bg.ac.rs/handle/123456789/3236
AB  - Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency  lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D  lt  19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D  lt  19.6 nmol/l had a significantly shorter PFS.
PB  - Springer, New York
T2  - Synthetic Communications
T1  - 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?
VL  - 26
IS  - 8
SP  - 2825
EP  - 2832
DO  - 10.1007/s00520-018-4101-9
ER  - 
@article{
author = "Đurasinović, Vladislava T. and Mihaljević, Biljana and Šipetić-Grujičić, Sandra B. and Ignjatović, Svetlana and Trajković, Goran and Todorović-Balint, Milena R. and Antić, Darko and Bila, Jelena S. and Anđelić, Bosko M. and Jelicić, Jelena J. and Vuković, Vojin M. and Nikolić, Aleksandra M. and Klek, Stanislaw",
year = "2018",
url = "http://farfar.pharmacy.bg.ac.rs/handle/123456789/3236",
abstract = "Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency  lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D  lt  19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D  lt  19.6 nmol/l had a significantly shorter PFS.",
publisher = "Springer, New York",
journal = "Synthetic Communications",
title = "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?",
volume = "26",
number = "8",
pages = "2825-2832",
doi = "10.1007/s00520-018-4101-9"
}
Đurasinović VT, Mihaljević B, Šipetić-Grujičić SB, Ignjatović S, Trajković G, Todorović-Balint MR, Antić D, Bila JS, Anđelić BM, Jelicić JJ, Vuković VM, Nikolić AM, Klek S. 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. Synthetic Communications. 2018;26(8):2825-2832
Đurasinović, V. T., Mihaljević, B., Šipetić-Grujičić, S. B., Ignjatović, S., Trajković, G., Todorović-Balint, M. R., Antić, D., Bila, J. S., Anđelić, B. M., Jelicić, J. J., Vuković, V. M., Nikolić, A. M.,& Klek, S. (2018). 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?.
Synthetic CommunicationsSpringer, New York., 26(8), 2825-2832.
https://doi.org/10.1007/s00520-018-4101-9
Đurasinović Vladislava T., Mihaljević Biljana, Šipetić-Grujičić Sandra B., Ignjatović Svetlana, Trajković Goran, Todorović-Balint Milena R., Antić Darko, Bila Jelena S., Anđelić Bosko M., Jelicić Jelena J., Vuković Vojin M., Nikolić Aleksandra M., Klek Stanislaw, "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?" 26, no. 8 (2018):2825-2832,
https://doi.org/10.1007/s00520-018-4101-9 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB